Denali Therapeutics Inc. - 10-Q Filing
Denali Therapeutics filed its 10-Q for the quarter ended March 31, 2026, providing unaudited financial results. The filing includes details on its financial position, including cash balances, marketable securities, and stockholder equity. It also outlines ongoing collaborative agreements with partners like Biogen, Sanofi, and Takeda, which include milestone and option fee payments. The company reported research and development expenses and general and administrative expenses for the first quarter of 2026.
Tickers: $DNLI